Ascendis Pharma A/S
ASND
Rank in Stocks
#1509
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Share Price
$230.45
Last synced: 2026-10-19
Market Cap
$14.37B
Change (1 day)
2.31%
Change (1 year)
12.30%
Country
DK
Trade Ascendis Pharma A/S (ASND)
Category
Healthcare
Stock split history for Ascendis Pharma A/S (ASND)
Ascendis Pharma A/S stock (symbol: ASND) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One ASND share bought prior to Oct 20, 2026 would equal to 0 ASND shares today.
The most recent stock split occurred on Oct 20, 2026.
One ASND share bought prior to Oct 20, 2026 would equal to 0 ASND shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
